Table 2.
The distribution of the clinical-pathological characteristics of thyroid cancer, n (%)
| Year of diagnosis | Total | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | P value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total | 15,000 | 151 | 574 | 691 | 847 | 1130 | 1770 | 2233 | 2265 | 2482 | 2857 | |
| Sex | ||||||||||||
| Male | 3195 (21.3) | 27 (17.9) | 102 (17.8) | 142 (20.6) | 185 (21.8) | 246 (21.8) | 430 (24.3) | 482 (21.6) | 484 (21.4) | 502 (20.2) | 595 (20.8) | 0.043 |
| Female | 11,805 (78.7) | 124 (82.1) | 472 (82.2) | 549 (79.4) | 662 (78.2) | 884 (78.2) | 1340 (75.7) | 1751 (78.4) | 1781 (78.6) | 1980 (79.8) | 2262 (79.2) | |
| Age groups | ||||||||||||
| Children (<18 years) | 40 (0.3) | 0 (0) | 0 (0) | 3 (0.4) | 3 (0.4) | 5 (0.4) | 4 (0.2) | 5 (0.2) | 9 (0.4) | 2 (0.1) | 9 (0.3) | <0.05 |
| Youth (19–44 years) | 8475 (56.5) | 86 (57.0) | 331 (57.7) | 390 (56.4) | 497 (58.7) | 635 (56.2) | 1018 (57.5) | 1334 (59.7) | 1298 (57.3) | 1394 (56.2) | 1492 (52.2) | |
| Middle age (45–59 years) | 5864 (39.1) | 57 (37.8) | 223 (38.9) | 267 (38.6) | 324 (38.3) | 434 (38.4) | 693 (39.2) | 823 (36.9) | 851 (37.6) | 979 (39.4) | 1213 (42.5) | |
| Elderly (60+ years) | 621 (4.1) | 8 (5.3) | 20 (3.5) | 31 (4.5) | 23 (2.7) | 56 (5.0) | 55 (3.1) | 71 (3.2) | 107 (4.7) | 107 (4.3) | 143 (5.0) | |
| Histological type | ||||||||||||
| PTC | 14,916 (99.4) | 146 (96.7) | 567 (98.8) | 684 (99.0) | 842 (99.4) | 1122 (99.3) | 1763 (99.6) | 2222 (99.5) | 2252 (99.4) | 2473 (99.6) | 2845 (99.6) | >0.05 |
| FTC | 6 (0.04) | 2 (1.3) | 1 (0.2) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (0.1) | 2 (0.1) | |
| MTC | 73 (0.5) | 1 (0.7) | 6 (1.1) | 7 (1.0) | 5 (0.6) | 8 (0.7) | 7 (0.4) | 9 (0.4) | 12 (0.5) | 8 (0.3) | 10 (0.4) | |
| ATC | 5 (0.03) | 2 (1.3) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 2 (0.09) | 1 (0.1) | 0 (0) | 0 (0) | |
| MTD (median, cm) | 0.6 | – | 0.8 | 0.7 | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | >0.05 |
| Multifocality | 6052 (40.4) | 40 (26.5) | 184 (32.1) | 272 (39.4) | 325 (38.4) | 425 (37.6) | 700 (39.5) | 963 (43.1) | 947 (41.8) | 1051 (42.3) | 1145 (40.1) | <0.05 |
| Extrathyroid extension | 2018 (13.5) | 4 (2.7) | 13 (2.3) | 41 (5.9) | 45 (5.3) | 102 (9.0) | 221 (12.5) | 236 (10.6) | 375 (16.6) | 427 (17.2) | 554 (19.4) | <0.05 |
| Nodular goiter present | 11,642 (77.6) | 126 (83.4) | 491 (85.5) | 406 (58.8) | 620 (73.2) | 913 (80.8) | 1435 (81.1) | 1777 (79.6) | 1664 (73.5) | 1822 (73.4) | 2388 (83.6) | >0.05 |
| Thyroiditis present | 3285 (21.9) | 48 (31.8) | 174 (30.3) | 201 (29.1) | 235 (27.7) | 255 (22.6) | 358 (20.2) | 402 (18) | 497 (21.9) | 481 (19.4) | 634 (22.2) | >0.05 |
| LNM | 6326 (42.2) | 44 (29.1) | 198 (34.5) | 299 (43.3) | 317 (37.4) | 404 (35.8) | 738 (41.7) | 968 (43.4) | 1039 (45.9) | 1095 (44.1) | 1224 (42.8) | <0.05 |
| Central LNM | 3706 (24.7) | 13 (8.6) | 96 (16.7) | 118 (17.1) | 104 (12.3) | 126 (11.2) | 340 (19.2) | 567 (25.4) | 622 (27.5) | 790 (31.8) | 930 (32.6) | |
| Lateral LNM | 2620 (17.5) | 31 (20.5) | 102 (17.8) | 181 (26.2) | 213 (25.1) | 278 (24.6) | 398 (22.5) | 401 (18) | 417 (18.4) | 305 (12.3) | 294 (10.3) | |
| Lobes of cancer | ||||||||||||
| Left lobe | 5012 (33.4) | 63 (41.7) | 199 (34.7) | 218 (31.6) | 278 (32.8) | 379 (33.5) | 619 (35.0) | 727 (32.6) | 761 (33.6) | 818 (33.0) | 950 (33.3) | <0.05 |
| Right lobe | 5731 (38.2) | 59 (39.1) | 238 (41.5) | 261 (37.8) | 309 (36.5) | 465 (41.2) | 652 (36.8) | 846 (37.9) | 820 (36.2) | 950 (38.3) | 1131 (39.6) | |
| Isthmus | 153 (1.0) | 6 (4.0) | 18 (3.1) | 17 (2.5) | 26 (3.1) | 15 (1.3) | 15 (0.9) | 16 (0.7) | 13 (0.6) | 12 (0.5) | 15 (0.5) | |
| Bilaterlity | 4100 (27.3) | 23 (15.2) | 119 (20.7) | 195 (28.2) | 232 (27.4) | 271 (24.0) | 484 (27.3) | 644 (28.8) | 670 (29.6) | 702 (28.3) | 760 (26.6) | |
| 8th AJCC/TNM stage | ||||||||||||
| Stage I | 14,383 (95.9) | 134 (88.7) | 545 (95.0) | 667 (96.5) | 825 (97.4) | 1089 (96.4) | 1715 (96.9) | 2139 (95.8) | 2165 (95.6) | 2366 (95.3) | 2738 (95.8) | <0.05 |
| Stage II | 531 (3.5) | 1 (0.7) | 19 (3.3) | 19 (2.8) | 18 (2.1) | 34 (3.0) | 52 (2.9) | 87 (3.9) | 89 (3.9) | 105 (4.2) | 107 (3.8) | |
| Stage III | 23 (0.2) | 2 (1.3) | 1 (0.2) | 2 (0.3) | 0 (0) | 2 (0.2) | 1 (0.1) | 3 (0.1) | 4 (0.2) | 5 (0.2) | 3 (0.1) | |
| Stage IV | 41 (0.3) | 2 (1.3) | 1 (0.2) | 3 (0.4) | 2 (0.2) | 5 (0.4) | 2 (0.1) | 4 (0.2) | 7 (0.3) | 6 (0.2) | 9 (0.3) | |
| Unknown | 22 (0.2) | 12 (8.0) | 8 (1.4) | 0 (0) | 2 (0.2) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | |
| Risk stratification of recurrence | ||||||||||||
| Low risk | 8761 (58.9) | 58 (39.2) | 380 (66.9) | 389 (57.1) | 498 (59.4) | 683 (61.2) | 1027 (58.4) | 1379 (62.2) | 1295 (57.7) | 1427 (57.7) | 1625 (57.3) | <0.05 |
| Intermediate risk | 5683 (38.2) | 86 (58.1) | 175 (30.8) | 268 (39.4) | 319 (38.0) | 403 (36.1) | 687 (39.1) | 778 (35.1) | 876 (39.1) | 967 (39.1) | 1124 (39.6) | |
| High risk | 438 (2.9) | 4 (2.7) | 13 (2.3) | 24 (3.5) | 22 (2.6) | 31 (2.8) | 45 (2.6) | 60 (2.7) | 72 (3.2) | 78 (3.2) | 89 (3.1) | |